piperonyl butoxide

Trade name: Rid Mousse

Small moleculeapproved

Approved

Mar 7, 2000

Piperonyl butoxide (PBO) is an organic compound used as a component of pesticide formulations. It is a waxy white solid. It is a semisynthetic derivative of safrole. It is used for the treatment of head, pubic (crab), and body lice. Piperonyl butoxide is a synergist. It has no pesticidal activity of its own, but acts to increase the activity of pesticides such as carbamates, pyrethrins, pyrethroids, and rotenone. PBO acts as an insecticide synergist by inhibiting the natural defense mechanisms of the insect, the most important of which is the Mixed Function Oxidase system, also known as the cytochrome P-450 system. The MFO system is the primary route of detoxification in insects, and causes the oxidative breakdown of insecticides like pyrethrins and the synthetic pyrethroids - thus when PBO is added, higher insecticide levels remain in the insect to exercise their lethal effect. An important consequence of this property is that, by enhancing the activity of a given insecticide, less may be used to achieve the same result. PBO does not appear to have a significant effect on the MFO system in humans. Skin Sensitization PBO has a low acute toxicity by oral, inhalation and dermal routes. It is minimally irritating to the eyes and skin. It is a not a dermal sensitizer. No evidence suggests that PBO disrupts the normal functioning of the endocrine system. This includes the recently developed data to assess the possible interaction of PBO with the endocrine system. — NCATS

Clinical trial activity

3 trials · 9 clinical orgs · 1 marketing orgs

Phase 1
0
Phase 2
0
Phase 3
1
Phase 4
0

Earliest trial started Sep 1, 2004 (NCT00381082)

Timeline

2000s

  1. Mar 7, 2000

    Bayer — Earliest FDA Approval

  2. Mar 7, 2000

    Bayer — NDA Secondary Org

  3. Mar 7, 2000

    Bayer — NDA Organization

  4. Jan 1, 2004

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Combination products

Approval history

  • approvedMar 7, 2000

Chemistry & pharmacology

Loading structure…

SMILES

CCCCOCCOCCOCC1=C(CCC)C=C2OCOC2=C1
Mol. weight
338.4385 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Delivery
Topical
Availability
Discontinued

Oral

No

Parenteral

No

Topical

Yes

Sources

Also known as

  • butacide
  • buticide
  • butocide
  • butoxide
  • butyl carbitol 6-propylpiperonyl ether
  • piperonyl
  • piperonyl butoxide
  • piperonyl butoxide
  • piperonyl butoxide
  • piperonyl butoxide
  • piperonyl butoxide
  • piperonyl butoxide
  • piperonyl butoxide
  • piperonyl butoxide
  • piperonyl butoxide
  • piperonyl butoxide
  • rid mousse

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT04566510N/AOct 17, 2020National Institute of Allergy and Infectious Diseases (NIAID), University of California, San Francisco, University of London
NCT03554616N/ADec 1, 2018Kilimanjaro Christian Medical College, Tanzania, National Institute for Medical Research, Tanzania, University of London, University of Ottawa
NCT00381082Phase 2/Phase 3 (Phase 3)Sep 1, 2004Ego Pharmaceuticals, Uniquest Pty Ltd, University of Queensland
Showing 3 of 3 trials
Page 1 / 1

Organizations

Research & Development (9)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
University of LondonAcademic/Hospital2112018
Ego PharmaceuticalsFor profit1012004
Kilimanjaro Christian Medical College, TanzaniaAcademic/Hospital1012018
National Institute for Medical Research, TanzaniaGovernment1012018
National Institute of Allergy and Infectious Diseases (NIAID)Government1012020
Uniquest Pty LtdAcademic/Hospital1112004
University of California, San FranciscoAcademic/Hospital1112020
University of OttawaAcademic/Hospital1012018
University of QueenslandAcademic/Hospital1012004
9 organizations
Page 1 / 1

Marketing (2)

OrganizationOrg typeRelationshipDate
BayerFor profitNDA2Mar 7, 2000
BayerFor profitNDAMar 7, 2000